Rosiglitazone, a peroxisome proliferator activator receptor gamma (PPARγ) agonist, targets adipose tissue and has been shown to reduce endothelin-1 and attenuate hypertension as well as renal inflammation and injury in SLE mice model (Venegas-Pont et al., 2009). The gene discussed is PPARG; the disease is hypertensive disorder.